ArticleNature2025
Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Meta-analysis of treatment-emergent seizures in glioma vaccine trials.Journal of neuro-oncology · 2026Pooled it
- Stroke drives glioma progression through the emergence of tumor-associated astrocytes with reduced CaNature cancer · 2026Article
- Advances in the role of astrocytes in glioma progression and therapy.Acta pharmacologica Sinica · 2026Review
- Glioma microenvironment: Cellular crosstalk, immunosuppression, and novel therapeutic perspectives.Chinese medical journal · 2026Review
- Antigen presentation by CD40Nature · 2026Article
- Astrocyte heterogeneity in brain metastases.Molecular oncology · 2026Review
- Beyond fibrosis: Emerging role of IL-11 in regulating innate and adaptive immune cell plasticity.Molecular biology reports · 2026Review
- Uncovering MYOF as a novel therapeutic target in glioblastoma: mechanistic insights and drug discovery.Cell death discovery · 2026Article
- Epithelial cancer cells co-opt the death ligand TRAIL to avert extrinsic apoptosis while acquiring killing capacity.Cell death and differentiation · 2026Article
- Leveraging multimodal cancer immunotherapy to amplify the efficacy of oncolytic viruses.Experimental hematology & oncology · 2026Review
- Review
- Metabolic Reprogramming and Neurotransmitter Signaling Co-Option in the Glioma Immune Microenvironment: Dual-Axis Regulation of Immunosuppression.Biomolecules · 2026Review
- Astrocyte-associated immunosuppressive programs in brain tumors: a STAT3-centered perspective.Cancer metastasis reviews · 2026Review
- Astrocyte-driven immunosuppression in the brain tumor microenvironment.Nature immunology · 2026Review
- Article
- Astrocytes in neuroinflammation and brain cancer.Molecular biomedicine · 2026Review
- Precision Immunotherapeutics for Glioblastoma: Current Approaches and Emerging Strategies in 2026.Cells · 2026Review
- Targeting immunosuppressive network in glioblastoma: Emerging strategies to overcome immunodeficiency and enhance therapeutic efficacy.Acta pharmaceutica Sinica. B · 2026Review
- Beyond Epilepsy Control: Repurposing Antiepileptic Drugs in Central Nervous System Tumor Therapy.Cells · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors.
Camilo Faust AklAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-5883-4441
Brian M AndersenAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Zhaorong LiAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Federico GiovannoniAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Martin DieboldInstitute of Neuropathology, University of Freiburg, Freiburg, Germany.ORCID 0000-0001-9636-6936
Liliana M SanmarcoAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Michael KilianAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-1946-3174
Luca FehrenbacherInstitute of Neuropathology, University of Freiburg, Freiburg, Germany.ORCID 0000-0002-2306-5718
Florian PerninNeuroimmunology Unit, Montreal Neurological Institute and Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.
Joseph M RoneAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0009-0001-9130-0249
Hong-Gyun LeeAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-5960-5504
Gavin PiesterAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jessica E KenisonAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Joon-Hyuk LeeAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Tomer IllouzAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-4123-6469
Carolina M PolonioAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Léna SrunAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jazmin MartinezAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Elizabeth N ChungAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Anton SchüleAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0009-0003-3094-9778
Agustin PlasenciaAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-7415-0947
Lucinda LiAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Kylynne FerraraAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Mercedes LewandrowskiProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.ORCID 0000-0003-2613-8860
Craig A StrathdeeOncorus, Andover, MA, USA.
Lorena LernerOncorus, Andover, MA, USA.ORCID 0000-0002-9474-2018
Christophe QuévaOncorus, Andover, MA, USA.
Iain C ClarkAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-9082-0253
Benjamin DeneenCenter for Cancer Neuroscience, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0002-6335-1081
Judy LiebermanProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.ORCID 0000-0002-6200-4715
David H SherrDepartment of Pathology, Boston University School of Medicine, Boston, MA, USA.
Jack P AntelNeuroimmunology Unit, Montreal Neurological Institute and Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.ORCID 0000-0002-5148-0636
Michael A WheelerAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-0689-6384
Keith L LigonDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0002-7733-600X
E Antonio ChioccaDepartment of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0001-5183-1670
Marco PrinzInstitute of Neuropathology, University of Freiburg, Freiburg, Germany.ORCID 0000-0002-0349-1955
David A ReardonCenter for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-6674-0157
Francisco J QuintanaAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. fquintana@rics.bwh.harvard.edu.ORCID 0000-0001-8156-0736
Funding
Targeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI KEITH LLOYD LIGON · 2013 to 2026
$33.5MTraining Program in Nervous System TumorsK12CA090354 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PLOTKIN, SCOTT R · 2001 to 2025
$16.3MAHR-mediated immunosuppression in glioblastomaR01ES029136 · NIEHS · BRIGHAM AND WOMEN'S HOSPITAL · PI Francisco J. Quintana, DAVID A REARDON · 2019 to 2026
$3.3MControl of extracellular matrix remodeling by CD29+ astrocytesR01MH130458 · NIMH · BRIGHAM AND WOMEN'S HOSPITAL · PI Michael Alex Wheeler · 2022 to 2026
$2.1MRegulation of CNS AutoimmunityR01AI126880 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI QUINTANA, FRANCISCO J. · 2017 to 2021
$2.1MControl of Local CNS InflammationR01NS102807 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI QUINTANA, FRANCISCO J. · 2018 to 2022
$1.8MA Psilocybin-Sensitive Neuroimmune Circuit Controlling Stress BehaviorsR01DA061199 · NIDA · BRIGHAM AND WOMEN'S HOSPITAL · PI Michael Alex Wheeler · 2024 to 2026
$1.7MControl of ETV1 transcriptional networks in amygdalar astrocytesR01MH132632 · NIMH · BRIGHAM AND WOMEN'S HOSPITAL · PI Michael Alex Wheeler · 2024 to 2026
$1.3MMolecular Control of Astrocytes in CNS InflammationR00NS114111 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI WHEELER, MICHAEL ALEX · 2023 to 2025
$783kNK killing of coronavirus-infected cellsF31AI176618 · NIAID · HARVARD MEDICAL SCHOOL · PI LEWANDROWSKI, MERCEDES · 2023 to 2025
$116kBLRD VA IK2 BX006568NCI NIH HHS K12 CA090354NCI NIH HHS P50 CA165962NIAID NIH HHS F31 AI176618NIAID NIH HHS R01 AI126880NIDA NIH HHS R01 DA061199NIEHS NIH HHS R01 ES029136NIMH NIH HHS R01 MH130458NIMH NIH HHS R01 MH132632NINDS NIH HHS L30 NS139299NINDS NIH HHS R00 NS114111NINDS NIH HHS R01 NS102807
Abstract
Glioblastoma is the most common and aggressive primary brain cancer and shows minimal response to therapies. The immunosuppressive tumour microenvironment in glioblastoma contributes to the limited therapeutic response. Astrocytes are abundant in the central nervous system and have important immunoregulatory roles. However, little is known about their role in the immune response to glioblastoma
Indexed as
AstrocytesBrain NeoplasmsGlioblastomaT-LymphocytesAnimalsApoptosisCell Line, TumorDisease Models, AnimalFemaleHerpesvirus 1, HumanHumansMacrophagesMaleMiceMice, Inbred C57BLOncolytic VirotherapySTAT3 Transcription FactorTNF-Related Apoptosis-Inducing LigandTNFSF10 protein, human
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.